Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials

doi:10.4330/wjc.v13.i10.585

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4556)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

291

WORD

HTML

2398

Figures (1-1)

151

Sum=2906

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

315

Download

504

Sum=819

Publishing Process of This Article

Item

Count

Browse

330

Download

498

Sum=828

Oct 26, 2021 (publication date) through May 20, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Cardiol. Oct 26, 2021; 13(10): 585-592
Published online Oct 26, 2021. doi: 10.4330/wjc.v13.i10.585

Open in New Tab Full Size Figure Download Figure

Figure 1 Effect of dipeptidyl peptidase-4 inhibitor treatment compared to control on the risk. A: Fatal and non-fatal myocardial infarction; B: Fatal and non-fatal stroke; C: Hospitalization for heart failure; D: Hospitalization due to unstable angina; E: Hospitalization for coronary revascularization; F: Cardiovascular mortality.

Citation: Patoulias DI, Boulmpou A, Teperikidis E, Katsimardou A, Siskos F, Doumas M, Papadopoulos CE, Vassilikos V. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J Cardiol 2021; 13(10): 585-592
URL: https://www.wjgnet.com/1949-8462/full/v13/i10/585.htm
DOI: https://dx.doi.org/10.4330/wjc.v13.i10.585